Physicians' Academy for Cardiovascular Education

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Video navigation menu

  • A heterogeneity is seen in the benefit of empagliflozin in patients with HF 0:21
  • Proposed mechanism of benefit before the EMPA-REG Outcome trial 1:14
  • The surprising results have changed ideas on the mechanism of empagliflozin 2:51
  • Is the proposed mechanism just a diuretic effect or due to lowering blood pressure? 7:54
  • Patients with diabetes have higher HF risk 9:44
  • Emerging concept on the mechanism of benefit of SGLT2 inhibition. 10:40